Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyorin Europe Starts Operations in Germany
March 25, 2002
- Bungyo Rate Up 4.8 Points to 45.5%
March 25, 2002
- Revision of Medical Fees to Change Outpatients Visiting Pattern
March 25, 2002
- Cost Calculation Method Needs Improvements: Dr Sugaya of JMA
March 25, 2002
- Operation of Hospitals by Profit-making Organizations Not Recommended
March 25, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 25, 2002
- Speed of Clinical Trials up to 18 Times Slower in Japan: Korosho
March 25, 2002
- Franchise Business GL Proposed by FTC
March 25, 2002
- Around 10% Price Reduction to Have Big Impact on Firms
March 25, 2002
- NID to Develop Product Information System "Drug Store Navi"
March 25, 2002
- Highest Price Reduction Rate Was 78.4%
March 25, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 25, 2002
- BUSINESS NEWS IN BRIEF
March 25, 2002
- MEDICAL DEVICE NEWS IN BRIEF
March 25, 2002
- Nippon Shinyaku Completes Renovation of Production Lines
March 25, 2002
- Nippon Roche to Participate in Multinational Study on Herceptin: JSMO Meeting
March 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 18, 2002
- REGULATORY NEWS IN BRIEF
March 18, 2002
- Committee to Propose Intellectual Property Strategy by Summer
March 18, 2002
- New NHI Prices to Be Effective on April 1
March 18, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…